[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574381":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":25,"studyPopulation":18,"armGroups":26,"interventions":33,"overallOfficials":18,"centralContacts":43,"locations":49,"responsibleParty":62,"collaborators":64,"id":68,"slug":18,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":18,"eligibilityCriteria":72,"healthyVolunteers":69,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":18,"studyType":79,"phases":80,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":51,"whyStopped":18,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Guangdong Provincial People's Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Safety and tolerability","Incidence rate of TRAE（Treatment-Related Adverse Event）","About 3 years",[14],{"measure":15,"description":16,"timeFrame":17},"Disease-free survival rate","Disease-free survival rates at 6, 12, 18, and 24 months","About 2 years",null,{"allocation":20,"interventionModel":21,"interventionModelDescription":18,"primaryPurpose":22,"observationalModel":18,"timePerspective":18,"maskingInfo":23},"NA","SINGLE_GROUP","TREATMENT",{"masking":24,"maskingDescription":18,"whoMasked":18},"NONE","This is a single-center, single-arm, open investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of resectable pancreatic cancer.\n\nThe study is planned to enroll 18 subjects. The entire study consists of a screening period of up to 28 days, treatment period, and a follow-up period (safety follow-up 28 days after the final study dose and survival follow-up once every 3 months).",[27],{"label":28,"type":29,"description":28,"interventionNames":30},"VRT106 combination with chemotherapy","EXPERIMENTAL",[31,32],"Drug: Oncolytic virus VRT106","Drug: Chemotherapy",[34,39],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":18},"DRUG","Oncolytic virus VRT106","VRT106, IV",[28],{"type":35,"name":40,"description":41,"armGroupLabels":42,"otherNames":18},"Chemotherapy","21 days\u002Fcycle, administered up to 6 cycles",[28],[44],{"name":45,"role":46,"phone":47,"phoneExt":18,"email":48},"Chen RF Prof.","CONTACT","020-83525210","chenrf63@163.com",[50],{"facility":5,"status":51,"city":52,"state":53,"zip":18,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":18},"RECRUITING","Guangzhou","Guangdong","China","CN",{"type":57,"coordinates":58},"Point",[59,60],113.25,23.11667,{"lat":60,"lon":59},{"type":63,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[65],{"name":66,"class":67},"Guangzhou Virotech Pharmaceutical Co., Ltd.","INDUSTRY","100574381",false,"NCT06758544","A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer","Inclusion Criteria:\n\n1. Subject voluntarily agrees to participate in this study and signs an Institutional Review Board -approved informed consent prior to performing any of the Screening Visit procedures.\n2. Males and females at 18-75 years of age, inclusive, at the Screening Visit.\n3. Have a clinical diagnosis of pancreatic cancer.\n4. An Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.\n5. Expected survival time of≥6 months.\n6. No serious hematologic and cardiac abnormalities of the liver, kidneys, or coagulation functions.\n\nExclusion Criteria:\n\n1. Prior treatment with other oncolytic virus or systemic therapy for pancreatic cancer.\n2. Previous allogeneic hematopoietic stem cell transplantation or organ transplantation.\n3. Immunocompromised patients.\n4. Known alcohol or drug dependency.\n5. Women who are pregnant or breastfeeding.","ALL","18 Years","75 Years",{"count":77,"type":78},18,"ESTIMATED","INTERVENTIONAL",[81,82],"PHASE1","PHASE2","This is a single-center, single-arm, open investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of resectable pancreatic cancer.",[85],"Pancreatic Cancer",[87],"Resectable pancreatic cancer","2025-08-13",{"date":90,"type":91},"2025-08-17","ACTUAL",{"date":93,"type":91},"2025-03-17",{"date":95,"type":78},"2026-11-30",{"name":5,"class":6},1]